The Business Behind...
Health Care: Drugs
Biogen Idec Inc (BIIB: NASDAQ)
$231.33 6.15 | 2.73%
05/21/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | 1.38B | 1.27B | 898.57M | 977.06M |
| Operating Gains/Losses | 0.00 | -15.06M | -8.87M | -23.97M |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 3.57M | -79.64M | -127.90M | -87.31M |
| (Increase) Decrease in Inventories | -140.31M | -59.22M | -4.53M | -42.77M |
| (Increase) Decrease In Other Current Assets | -39.67M | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 0.00 | 0.00 | 130.88M | 0.00 |
| (Decrease) Increase In Other Current Liabilities | 307.48M | 33.72M | 0.00 | 696.46M |
| (Increase) Decrease In Other Working Capital | -27.35M | -79.48M | 5.11M | -917.86M |
| Other Non-Cash Items | 147.39M | 148.22M | 458.72M | 182.68M |
| Net Cash From Continuing Operations | 1.88B | 1.73B | 1.62B | 1.07B |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | 1.88B | 1.73B | 1.62B | 1.07B |
| Sale of Property, Plant & Equipment | 0.00 | 2.21M | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 2.28B | 2.67B | 3.32B |
| Purchases of Property, Plant & Equipment | -261.18M | -252.18M | -173.06M | -165.65M |
| Acquisitions | -72.40M | -5.00M | -157.43M | 0.00 |
| Purchases of Short-Term Investments | 0.00 | -3.70B | -1.99B | -3.55B |
| Other Cash from Investing Activities | 2.75B | 0.00 | -4.49M | 29.99M |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -950.34M | -1.65B | 345.32M | -395.03M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 67.49M | 314.65M | 183.49M | 47.81M |
| Repayment of Long-Term Debt | -2.43M | -11.46M | -18.07M | -10.87M |
| Repurchase of Capital Stock | -984.72M | -497.98M | -2.08B | -751.17M |
| Payment of Cash Dividends | -2.73M | -27.06M | -23.48M | 0.00 |
| Other Financing Charges, Net | 44.90M | -98.02M | 150.72M | -9.92M |
| Net Cash From Financing Activities | -877.48M | -319.86M | -1.78B | -724.15M |
| Effect of Exchange Rate Changes | 4.10M | -2.64M | -7.37M | 3.79M |
| Net Change in Cash & Cash Equivalents | 56.18M | -245.06M | 177.71M | -40.50M |
Portfolios with BIIB
- Portfolio NameUser Type
- User4 Overvalued Biotechs
- UserCorgies Follies
- ProNavellier & Associates
- UserMy SP portfolio
- ContributorDrugs Facing FDA Approval i...
- Contributor22 Biopharma Stocks With Br...
- UserKAREL VON ZOETE
- UserEverett Bishop Portfolio 1
- ProViking Global Investors
- ContributorTop-Rated Biotechnology Stocks
Latest BIIB Headlines from TheStreet
- AGN, LLY, BIIB, CELG And AMGN, Pushing Health Care Sector Downward 05.16.13 | 01:05 pm
- Biogen Idec Inc (BIIB): Today's Featured Health Care Laggard 05.15.13 | 05:05 pm
- Cramer's 'Mad Money' Recap: Stick With What Works 05.14.13 | 08:05 pm
- Biogen Idec Stock Hits New 52-Week High (BIIB) 05.14.13 | 10:05 am
- Cramer: Biotech Makes a Comeback 05.10.13 | 04:05 pm
- 'Mad Money' Lightning Round: Buy, Buy, Buy Biogen 05.10.13 | 06:05 am
- Cramer's 'Mad Money' Recap: Looking for Real Leaders 05.09.13 | 08:05 pm
- Biogen Idec Inc (BIIB): Today's Featured Drugs Laggard 05.07.13 | 05:05 pm
- Cramer's 6 Stocks in 60 Seconds: BIIB CLF UNH BAC GRPN ADT (Update 1) 05.06.13 | 05:05 pm
- 5 Stocks Dragging In The Health Care Sector 05.06.13 | 01:05 pm
Press Releases for BIIB
- Image Of Biogen Idec's TECFIDERA(TM) (dimethyl Fumarate) Which Was Approved By The U.S. FDA On March 27, 2013 For Relapsing Multiple Sclerosis. (Photo: Business Wire) - Business Wire 03.27.13 | 04:03 pm
- CHMP Issues Positive Opinion For TECFIDERA™ (Dimethyl Fumarate) As A First-Line Treatment For Multiple Sclerosis In The European Union - Business Wire 03.22.13 | 08:03 am
- Positive Year One Results From Biogen Idec Phase 3 ADVANCE Trial Of PLEGRIDY™ (Peginterferon Beta-1a) Presented At AAN Meeting - Business Wire 03.20.13 | 07:03 am
- US Patent Office Grants Patent Claiming Dosing Regimen For TECFIDERA™ (Dimethyl Fumarate) - Business Wire 03.19.13 | 04:03 pm
- New TYSABRI Data Reaffirm Substantial Efficacy In Treatment Of People With MS And Demonstrate Stability Of Anti-JCV Antibody Status - Business Wire 03.18.13 | 07:03 am
- Biogen Idec To Present New Data On Diverse Neurological Portfolio At 65th AAN Annual Meeting - Business Wire 03.06.13 | 01:03 pm
- FDA Accepts Biogen Idec’s Biologics License Application For First Long-Lasting Factor IX Therapy For Hemophilia B - Business Wire 03.04.13 | 07:03 am
- Biogen Idec To Present At The Cowen And Company 33rd Annual Healthcare Conference - Business Wire 02.27.13 | 04:02 pm
- Biogen Idec To Present At The 2013 RBC Capital Markets Global Healthcare Conference - Business Wire 02.20.13 | 04:02 pm
- Biogen Idec To Present At The Citi 2013 Global Healthcare Conference - Business Wire 02.19.13 | 04:02 pm
Partner Headlines for BIIB
- Indexes Notch Sharp Declines; New 52-Week Low For Apple - Investor's Business Daily 04.17.13 | 04:04 pm
- Biotech Alkermes Poised To Swell On Pipeline Wins - Investor's Business Daily 04.16.13 | 05:04 pm
- Big Cap Leaders Slide But Show Little Technical Damage - Investor's Business Daily 04.15.13 | 07:04 pm
- Pockets of Strength In Top Groups, Few Leaders Basing - Investor's Business Daily 04.15.13 | 06:04 pm
- Sellers Smack Indexes Lower; Gold, Growth Names Slump - Investor's Business Daily 04.15.13 | 05:04 pm
- Acorda: A Biotech Company To Consider - Seeking Alpha 04.13.13 | 09:04 am
- Stocks End With Mild Losses; Nasdaq Rises 2.8% For Week - Investor's Business Daily 04.12.13 | 05:04 pm
- Stocks Lift Off Session Lows; Proto Labs Tumbles - Investor's Business Daily 04.12.13 | 01:04 pm
- Stocks Slip In Mixed Trade; Sinclair Broadcast Hits New High - Investor's Business Daily 04.12.13 | 11:04 am
- Benzinga's Top Pre-Market Gainers - Benzinga 04.12.13 | 09:04 am
